349 related articles for article (PubMed ID: 15779421)
21. [Treatment for coronary artery disease patients with impaired glucose tolerance].
Kume A; Miyazaki T; Daida H
Nihon Rinsho; 2005 Feb; 63 Suppl 2():543-7. PubMed ID: 15779438
[No Abstract] [Full Text] [Related]
22. [alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].
Odaka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():393-8. PubMed ID: 12387024
[No Abstract] [Full Text] [Related]
23. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose.
Frantz S; Calvillo L; Tillmanns J; Elbing I; Dienesch C; Bischoff H; Ertl G; Bauersachs J
FASEB J; 2005 Apr; 19(6):591-3. PubMed ID: 15671153
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of acarbose efficacy and safety for treatment of diabetes mellitus. Testing of observations under general health care conditions].
Sieradzki J; Soszyński P
Przegl Lek; 1999; 56(5):335-41. PubMed ID: 10554569
[TBL] [Abstract][Full Text] [Related]
25. [Acarbose--an effective drug for the prevention of type 2 diabetes and cardiovascular diseases?].
Laakso M
Duodecim; 2003; 119(20):1921-3. PubMed ID: 14639996
[No Abstract] [Full Text] [Related]
26. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
27. Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats.
Nakamura K; Yamagishi S; Matsui T; Inoue H
Drugs Exp Clin Res; 2005; 31(4):155-9. PubMed ID: 16223205
[TBL] [Abstract][Full Text] [Related]
28. alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.
Casirola DM; Ferraris RP
Metabolism; 2006 Jun; 55(6):832-41. PubMed ID: 16713445
[TBL] [Abstract][Full Text] [Related]
29. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.
Vannasaeng S; Ploybutr S; Nitiyanant W; Peerapatdit T; Vichayanrat A
J Med Assoc Thai; 1995 Nov; 78(11):578-85. PubMed ID: 8576667
[TBL] [Abstract][Full Text] [Related]
30. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Yamamoto M; Otsuki M
Metabolism; 2006 Apr; 55(4):533-40. PubMed ID: 16546485
[TBL] [Abstract][Full Text] [Related]
31. A review of the safety and efficacy of acarbose in diabetes mellitus.
Yee HS; Fong NT
Pharmacotherapy; 1996; 16(5):792-805. PubMed ID: 8888075
[TBL] [Abstract][Full Text] [Related]
32. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
Holman RR; Bethel MA; Chan JC; Chiasson JL; Doran Z; Ge J; Gerstein H; Huo Y; McMurray JJ; Ryden L; Liyanage W; Schröder S; Tendera M; Theodorakis MJ; Tuomilehto J; Yang W; Hu D; Pan C;
Am Heart J; 2014 Jul; 168(1):23-9.e2. PubMed ID: 24952856
[TBL] [Abstract][Full Text] [Related]
33. Reduction of postprandial hyperglycemia in patients with type 2 diabetes reduces NF-kappaB activation in PBMCs.
Rudofsky G; Reismann P; Schiekofer S; Petrov D; von Eynatten M; Humpert PM; Isermann B; Müller-Hoff C; Thai TP; Lichtenstein S; Bärtsch U; Hamann A; Nawroth P; Bierhaus A
Horm Metab Res; 2004 Sep; 36(9):630-8. PubMed ID: 15486815
[TBL] [Abstract][Full Text] [Related]
34. Seven-day subcutaneous continuous glucose monitoring demonstrates that treatment with acarbose attenuates late dumping syndrome in a woman with gastrectomy for gastric cancer.
Buscemi S; Mattina A; Genova G; Genova P; Nardi E; Costanzo M
Diabetes Res Clin Pract; 2013 Jan; 99(1):e1-2. PubMed ID: 23146372
[No Abstract] [Full Text] [Related]
35. Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the Early Diabetes Intervention Program.
Kirkman MS; Shankar RR; Shankar S; Shen C; Brizendine E; Baron A; McGill J
Diabetes Care; 2006 Sep; 29(9):2095-101. PubMed ID: 16936159
[TBL] [Abstract][Full Text] [Related]
36. [Heart failure and abnormal glucose metabolism].
Jiyoong K; Kitakaze M
Nihon Rinsho; 2007 May; 65 Suppl 5():581-7. PubMed ID: 17569330
[No Abstract] [Full Text] [Related]
37. Successful use of acarbose to manage post-prandial glycaemia in two patients with type 1 diabetes on continuous subcutaneous insulin infusion.
Dash S; Crisp S; Hartnell S; Donald S; Davenport K; Simmons D; Evans M
Diabetes Res Clin Pract; 2012 Mar; 95(3):e49-51. PubMed ID: 22136721
[TBL] [Abstract][Full Text] [Related]
38. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.
Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
Lancet; 2002 Jun; 359(9323):2072-7. PubMed ID: 12086760
[TBL] [Abstract][Full Text] [Related]
39. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
40. Alpha-glucosidase inhibitors may reduce the risk of type 2 diabetes.
Servey JT
Am Fam Physician; 2007 Aug; 76(3):374-5. PubMed ID: 17708136
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
